The dopamine (DA) transporter (DAT), which mediates the inactivation of released DA through its reuptake, is a primary molecular target for psychostimulants. 1, 2 Cocaine and methylphenidate (MPH) exert their psychostimulant properties by blocking DA reuptake, leading to the elevation of extracellular DA. 2 In contrast, amphetamine (AMPH) acts as a substrate for DAT and subsequently induces non-exocytotic DAT-mediated release of DA (DA efflux). 2 Here we use a Drosophila behavioral assay to delineate the signaling mechanisms that modulate DAT-mediated AMPH-induced behavior in vivo. Understanding these mechanisms is critical to understanding how the actions of AMPH might be blocked therapeutically, while simultaneously preserving DA transport. Multiple lines of evidence suggest that kinase activity can modulate DAT function and, more specifically, AMPH action on DAT. Both calcium/calmodulin kinase II alpha (CaMKII) and protein kinase C (PKC) can phosphorylate an N-terminal DAT peptide in vitro 3 and inhibiting the activity of either kinase attenuates AMPH-induced DA efflux in rodent striatial slices. 3, 4 Data from CaMKII and PKC knockout mice suggest a role for these kinases in regulating AMPH action in vivo. 5, 6 However, it is difficult to ascertain from these studies using global knockout strategies whether the observed effects on AMPH-induced DA efflux are mediated directly through alterations in DAT phosphorylation or whether they arise indirectly through phosphorylation of other targets or through circuit effects.
Recently we showed that phosphorylation of the N-terminus of DAT is essential for AMPH-induced, but not MPH-induced hyperlocomotion in Drosophila. Larvae respond to either AMPH or MPH by increasing their crawling velocity, and a null mutation in Drosophila DAT (dDAT fmn ) abolishes these locomotor responses. 7 Expression of wild-type human (hDAT) in DA neurons of dDAT fmn mutants rescues the response to either psychostimulant. 7 In contrast, expression of a phospho-deficient mutant hDAT (hDAT-S/A) rescued only the response to MPH but not to AMPH, 7 consistent with studies showing that DAT phosphorylation is required for AMPH-induced DA efflux but not for DA reuptake in heterologous cultured cells. 3, 8 Using the tractable Drosophila system, we have now determined whether CaMKII is required specifically in DA neurons for AMPH-induced behavior. To inhibit the activity of CaMKII, we used a UAS-driven highly selective inhibitory peptide (CaMKIINtide). 9 We expressed CaMKIINtide in DA neurons of larvae using the tyrosine hydroxylase (TH) GAL4 driver. 10 These larvae were fed either vehicle or AMPH and their speed of locomotion was measured as previously described. 7 Larvae expressing CaMKIINtide in DA neurons (UASCaMKIINtide(2x)/TH-GAL4) failed to increase their crawling velocity in response to AMPH in contrast to control larvae without TH-Gal4 (UAS-CaMKIINtide(2x)/ þ ), which exhibited significant hyperlocomotion ( Figure 1a) . Expression of CaMKIINtide in DA neurons did not inhibit MPH-induced hyperlocomotion (Figure 1b) , consistent with our previous finding that phosphorylation of DAT is not required for the behavioral response to this DA uptake inhibitor. 7 We also found that co-expression of CaMKIINtide with hDAT in DA neurons of mutant larvae that lack dDAT (dDAT fmn ; TH-GAL4,UAShDAT/UAS-CaMKIINtide(2x)) blunted AMPH-induced but not MPHinduced hyperlocomotion (Figures 1c and d , respectively). These data show that CaMKII is essential specifically in DA neurons for both dDAT-mediated and hDAT-mediated AMPH-induced hyperlocomotion in Drosophila. They also suggest that CaMKII activity is not required for DA uptake in vivo, as the response to MPH was unaffected in its absence.
To examine whether the role of CaMKII is mediated via DAT phosphorylation, we determined whether pseudophosphorylation of the DAT N-terminus can decouple the AMPH-induced behavior from the activation state of CaMKII. Previously we demonstrated that a mutant hDAT (hDAT-S/D), which mimics constitutive phosphorylation by mutation of the five N-terminal serines to aspartates, could restore AMPH-induced hyperlocomotion in dDAT mutant larvae. 7 When we expressed hDAT-S/D in animals where CaMKII was inhibited (dDAT fmn ; TH-GAL4, UAS-hDAT-S/D/UASCaMKIINtide(2x)) we found that the response to AMPH was restored (Figure 1e ). In contrast, larvae expressing wild-type hDAT (dDAT fmn ; TH-GAL4,UAS-hDAT/UAS-CaMKIINtide(2x)) failed to respond to AMPH (Figure 1e ). These data, combined with in vitro studies that show that CaMKII associates with the C-terminus of DAT and phosphorylates an N-terminal DAT peptide, 3 suggest that CaMKII mediates AMPH-induced hyperlocomotion by promoting DAT phosphorylation, although further experiments will be required to confirm CaMKII-mediated DAT phosphorylation in vivo.
The role of PKC in DAT phosphorylation and AMPH-induced DA efflux remains unclear. The two kinases might act in parallel given their demonstrated ability to phosphorylate DAT, 3 although our data suggest a more complex interaction, as AMPH-induced hyperlocomotion is completely blocked by CaMKIINtide. A PKC-mediated mechanism should not be blocked unless CaMKII functions downstream of the actions of PKC. Furthermore, expressing a PKC inhibitor peptide 11 in DA neurons of larvae (UAS-PKCi/TH-GAL4) did not inhibit the AMPH-induced hyperlocomotion; larvae exhibited a 24% increase in speed (Po0.001) upon AMPH treatment (data not shown). Still, although this construct has previously been shown to inhibit PKC function, 11 it is unclear whether it targets all fly PKC isoforms, of which there are at least five that may play redundant and/or compensatory roles. 12 Therefore, further experiments will be required to determine the precise role of PKC in AMPH-induced behavior.
Understanding the mechanisms that modulate CaMKII activity in response to AMPH will be critical for understanding the actions of AMPH and how they can be blocked therapeutically. This may be particularly relevant in the case of AMPH-induced sensitization, as signaling through CaMKII can play a key role in regulating synaptic plasticity. 13 Furthermore, as the signaling pathways that regulate efflux become clearer, it is possible that a physiological role for DA efflux through DAT, independent of its role in psychostimulant action, might be revealed.
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(c) CaMKIINtide driven by TH-GAL4 inhibited the AMPH response mediated by human DAT (hDAT). (d) CaMKIINtide driven by TH-GAL4 did not inhibit the MPH response mediated by hDAT. (e) Expression of mutant hDAT-S/D
rescued the response to AMPH that was blunted by CaMKIINtide. In all panels, UAS-CaMKIINtide indicates larvae carrying 2 copies of the transgene. Boxplots represent the median as the middle line, with the lower and upper edges of the boxes representing the 25% and 75% quartiles, respectively, and the whiskers representing the 5% and 95% quantiles. Asterisks indicate the statistical significance of the difference in mean velocity of larvae-fed drug as compared to larvae of the same genotype-fed vehicle, as determined using the nonparametric Mann-Whitney-Wilcoxon test using GraphPad Prism (NS P40.05, ***Po0.001).
Methylation of the promoter of brain-derived neurotrophic factor exon IV and antidepressant response in major depression Insufficient response to antidepressant pharmacotherapy with monoaminergic drugs is a major problem in the therapy of major depression (MD), occurring in up to two-thirds of depressed patients. To date, there is no biological marker reliably determining patients at high risk to treatment failure. Here, we report the first preliminary evidence that patients showing hypomethylation of the promoter region of the brain-derived neurotrophic factor (BDNF) gene are unlikely to benefit from antidepressant pharmacotherapy.
Several lines of evidence have linked the neurotrophin BDNF with both the pathophysiology of depression and the mode of action of antidepressants. 1 Effective antidepressive treatment seems to increase peripheral BDNF levels. 2, 3 We have shown earlier that the non-increase of BDNF in serum 4 or plasma 5 during the first week of antidepressant treatment predicts the final nonresponse and non-remission with high sensitivity, suggesting that early changes in peripheral BDNF may constitute or reflect a necessary prerequisite for final treatment response. For the complex regulation of BDNF expression by methylation of DNA and histone modifications, exon IV has a dominant role. 6, 7 However, almost all evidence regarding these effects has been derived from animal studies. So far, clinical studies in the field showed that (i) methylation profiles of bdnf exon I can distinguish between depressed patients and healthy controls, 8 and (ii) responders to treatment with antidepressants display a decrease in bdnf exon IV-related trimethylation at histone H3. 9 In order to assess whether DNA methylation of bdnf exon IV promoter in patients with MD affects antidepressant treatment response, we determined the methylation status in leukocytes of 13 cytosine-phosphate-guanine (CpG) sites within the bdnf exon IV promoter 10 in the same sample of patients with MD, which has served for the investigation of the impact of early peripheral BDNF changes on final response to antidepressant pharmacotherapy (see also Supplementary information). 4, 5 The intent-to-treat sample consisted of 46 patients with MD; 4, 5 owing to the missing methylation data at baseline (BL) in seven patients, the final sample consisted of 39 patients (20/19 female/ male participants; mean age±s.d. ¼ 44.9±12.7; mean Hamilton Depression Rating Scale-21 items version sum score at BL ± s.d. ¼ 20.4 ± 4.5; mean time to end point (EP) ± s.d. ¼ 4.2 weeks; range 2-6 weeks). Of the 13 investigated CpG sites, 12 yielded sufficient measurements; the CpG at position þ 42 was dropped from the analysis. The BL methylation status at CpG position À 87 predicted antidepressant non-response: final nonresponders had a significantly lower methylated C-fraction than final responders (Figure 1a) . Patients without methylation at CpG site À 87 had a significantly higher risk for non-response than those with any methylation (Figure 1b) . There was no significant interaction of gender or class of antidepressant with the association of CpG-87 methylation status and response at EP (CpG-87* gender: w 2 : 1.53; P ¼ 0.217; CpG-87*class of antidepressant: w 2 : 1.66; P ¼ 0.437). These results were also found for final non-remission with a similar effect size (data not shown).
Furthermore, patients with an unmethylated CpG site À 87 showed a marked, but statistically not significant (P ¼ 0.08), decrease of plasma BDNF levels during the first week of treatment (Figure 1c) . DNA methylation of the 12 investigated CpG sites in bdnf exon IV promoter did not change significantly during antidepressant treatment between BL and EP (Figure 1d) .
For further analysis, we cloned the bdnf exon IV promoter fragment into a pGL4 luciferase expression vector and tested the effect of methylation of the whole vector on antidepressantinduced changes in luciferase expression in a neuroblastoma cell line (SH-SY5Y) (see also Supplementary information). We found a significant decrease of luciferase expression after 48-h incubation with fluoxetine or venlafaxine in the unmethylated fragment only, whereas antidepressants did not change expression levels when the promoter fragment was methylated (Figure 1e) .
Our results are supported by a strong neurobiological framework, linking antidepressant response to the ability of an antidepressant to increase BDNF expression. Apart from the well-known pathway via 3 0 ,5 0 -cyclic adenosine monophosphate (cAMP)-mediated activation of cAMP response element-binding protein, antidepressants can also increase BDNF expression via phosphorylation of methyl-CpGbinding protein 2 (MeCP2) which-in its unphosphorylated formbinds to the promoter and forms a repressor complex, but dissociates from the DNA upon phosphorylation. 11 Thus, as methylation of
